Source: China.org.cn

In September 2020, Innovita (Tangshan) Biological Technology Co., Ltd. of Hebei Province was honored as the national advanced collective for fight against COVID-19, which is the only enterprise of in vitro diagnostic reagents obtaining this great honor in Hebei Province. 

"Since the outbreak of COVID-19 epidemic, Innovita (Tangshan) Biological Technology Co., Ltd. jumped into action, took advantage of its technical focus on the diagnostic reagents for respiratory infectious diseases for many years, and urgently transferred its elites to step up scientific research and tackle the key research project. " , said the relevant responsible persons of INNOVITA. 

INNOVITA has a specialist scientific research team formed by doctors and senior technological professionals. All members of the R&D team gave up their holidays and hurried off to the R&D Center from different places to return to their posts in short notice and fully committed themselves to the 2019-nCoV test reagent R&D. It was a race against time and against the rapid spread of the virus. INNOVITA relied on its technical advantages of respiratory diagnostic reagents, took the risk of being infected by virus, and overcame difficulties and challenges. From the raw material screening to process optimization, and then to clinical validation, finally, it successfully developed 2019-nCoV Antibody Test Kit. 

"On February 9, 2020, the product passed by the expert defense from the National Medical Products Administration. On February 11, the product was identified as a national key scientific and technological project by the Ministry of Science and Technology. On February 22, the 2019-nCoV Antibody Test Kit developed by INNOVITA emerged victorious among numerous products for declaration in the country. Since then, INNOVITA became one of two companies in the first batch obtaining the registration certificate for 2019-nCoV Antibody Testing Reagent. In a news conference, a well-known expert recognized the diagnostic effect of INNOVITA's 2019-nCoV Antibody Test Kit by name. " said relevant responsible person of INNOVITA. 

Different from the familiar 2019-nCoV nucleic acid testing reagents, what INNOVITA developed is 2019-nCoV Antibody Testing Reagents. In the 2019-nCoV testing, it can detect IgM antibody existing in the patient's body. Moreover, it is able to detect IgM antibody on the 7^th day of infection or the 3^rd day of onset, so as to provide a basis of more comprehensive reference for clinical diagnosis. 

Innovita (Tangshan) Biological Technology Co., Ltd. is a high-tech enterprise specialized in R&D, manufacturing and sales of POCT in vitro diagnostic products. It is in possession of multiple production lines including colloidal gold, ELISA, PCR and other diagnostic reagents, which is one of key enterprises in the industry of in vitro diagnostic reagents in Hebei Province. Since February of this year, INNOVITA has accumulatively produced the testing reagents for over ten million persons, and exported them to over 70 countries and regions all over the world, playing an important role in supporting the worldwide COVID-19 prevention and control. 

In early August 2021, INNOVITA's 2019-nCoV Antigen Testing Reagent was approved respectively by ANSM and Thai FDA. So far, INNOVITA's 2019-nCoV testing reagent has obtained the registration licenses from nearly 30 countries. 

These countries include the United States, Brazil, France, Italy, Russia, Spain, Portugal, the Netherlands, Hungary, Austria, Sweden, Singapore, the Philippines, Malaysia, Thailand, Argentina, Ecuador, Colombia, Peru, Chile, Mexico, etc. INNOVITA currently is also accelerating its application for registration with more countries and institutions, and expanding its scale of overseas registration of 2019-nCoV testing reagents, including application for CE certification of EU, the US FDA registration of 2019-nCoV Antigen Testing Reagent, etc. 

These testing reagents can achieve accurate, rapid and large-scale investigation and screening of 2019-nCoV, playing an important role in the fight against COVID-19 in China and other countries.